Hong Kong Stock Alert | TRANSTHERA-B (02617) Falls Over 10% Again, Plans Share Placement to Raise Net HKD 1.9 Billion Primarily for Core Product R&D

Stock News01-20

TRANSTHERA-B (02617) dropped more than 10% again. As of the time of writing, the stock was down 9.02%, trading at HKD 84.7, with a turnover of HKD 117 million. The company previously announced its intention to place 21 million new shares at a price of HKD 92.85 per share. This represents a 17.98% discount to the H-share closing price of HKD 113.2 on January 13. The net proceeds from the placement are estimated to be HKD 190 million. Approximately 60% of the proceeds will be used to fund the ongoing clinical trial in China for its core product, Tinengotinib, as a monotherapy for cholangiocarcinoma (CCA), as well as research and development for other indications of the core product. About 30% will be allocated to the R&D of other products, including TT-00973, TT-01488, and other molecules. Roughly 10% is designated for working capital and general corporate purposes.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment